医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Agilent Named One of Singapore’s Best Employers

2021年04月14日 AM09:00
このエントリーをはてなブックマークに追加


 

SINGAPORE

Agilent Technologies Inc. (NYSE: A) today announced that Agilent Singapore has been recognized as one of Singapore’s Best Employers in 2021 for the second year-in-a-row by The Straits Times, a leading Singapore-based newspaper. Specifically, Agilent is ranked among the top 100 companies and fifth out of eight in the Drugs & Biotechnology category.

“This year, Agilent Singapore is among the top 100 positions compared to our 108th ranking last year, so we’ve continued to excel—even during COVID,” said Woai-Sheng Chow, Agilent Singapore Vice President and General Manager, Global Instrument Manufacturing. “We are enormously proud of our employees.”

Rankings were determined on the results of an extensive independent survey conducted by the newspaper and Statista, a global research firm. The survey included more than 9,000 employees working at companies with more than 200 people. Employees were consulted anonymously through several online panels and through The Straits Times website. In total, more than 200,000 recommendations were evaluated, based on two distinct criteria. The first was a “direct recommendation,” an employee’s willingness to recommend their company to friends and family. The second was an “indirect recommendation,” an employee’s evaluation of other employers in their respective industries.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom.

Follow Agilent on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210413006097/en/

CONTACT

Media Contact

Tom Beermann

Agilent Technologies

+1.408.553.2914

tom.beermann@agilent.com

Media Contact

Soo-Chun Tan

Agilent Technologies – Singapore

+65 6276 2622

soo-chun.tan@agilent.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表